Provision for Income Taxes (Details Textual) |
12 Months Ended |
|---|---|
|
Dec. 31, 2019
USD ($)
| |
| Provision for Income Taxes (Textual) | |
| Net operating loss carryforwards | $ 26,700,000 |
| Research and development tax credit carryforwards | 197,747 |
| Valuation allowance | $ 1,357,874 |
| Corporation rate, percentage | 50.00% |
| Provision for income taxes, description | Begin to expire in years 2035 and 2020, respectively. The Company also has estimated available research and development tax credit carryforwards for federal income tax purposes of $197,747, which begin to expire in year 2032. |
| Income tax, period | P3Y |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|